Immune and Inflammatory Pathways in Non-Alcoholic Steatohepatitis (NASH). An Update
Highlights
- One of the possible mechanisms responsible for the activation of the immune system through intestinal microbiota is the activation of IL17 axis.
- Another possibility is represented by activation of the TLRs, with further studies being necessary to clarify these perspectives.
Abstract
:Highlights
- ✔
- One of the possible mechanisms responsible for the activation of the immune system through intestinal microbiota is the activation of IL17 axis.
- ✔
- Another possibility is represented by activation of the TLRs, with further studies being necessary to clarify these perspectives.
Abstract
1. Introduction
2. Discussions
3. Conclusions
Conflicts of Interest disclosure
Compliance with ethical standards
References
- Chackelevicius, C.M.; Gambaro, S.E.; Tiribelli, C.; Rosso, N. Th17 involvement in nonalcoholic fatty liver disease progression to non-Alcoholic steatohepatitis. World J Gastroenterol. 2016, 22, 9096–9103. [Google Scholar] [CrossRef]
- LaBrecque, D.R.; Abbas, Z.; Anania, F.; Ferenci, P.; Khan, A.G.; Goh, K.L.; Hamid, S.S.; Isakov, V.; Lizarzabal, M.; Peñaranda, M.M.; Ramos, J.F.; Sarin, S.; Stimac, D.; Thomson, A.B.; Umar, M.; Krabshuis, J.; LeMair, A.; Review Team; World Gastroenterology Organisation. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014, 48, 467–473. [Google Scholar] [CrossRef] [PubMed]
- Rinella, M.E. Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease? Hepatology. 2011, 54, 1118–1120. [Google Scholar] [CrossRef] [PubMed]
- Arrese, M.; Cabrera, D.; Kalergis, A.M.; Feldstein, A.E. Innate Immunity and Inflammation in NAFLD/NASH. Dig Dis Sci. 2016, 61, 1294–1303. [Google Scholar] [CrossRef] [PubMed]
- Tilg, H.; Moschen, A.R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology. 2010, 52, 1836–1846. [Google Scholar] [CrossRef]
- Kawai, T.; Akira, S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol. 2010, 11, 373–384. [Google Scholar] [CrossRef]
- Alisi, A.; Carsetti, R.; Nobili, V. Pathogen- or damage- associated molecular patterns during nonalcoholic fatty liver disease development. Hepatology. 2011, 54, 1500–1502. [Google Scholar] [CrossRef]
- Guo, J.; Friedman, S.L. Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis Tissue Repair. 2010, 3, 21. [Google Scholar] [CrossRef]
- Du, W.J.; Zhen, J.H.; Zeng, Z.Q.; Zheng, Z.M.; Xu, Y.; Qin, L.Y.; Chen, S.J. Expression of interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection. Diagn Pathol. 2013, 8, 40. [Google Scholar] [CrossRef]
- Farrell, G.C.; Larter, C.Z. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 2006, 43 Suppl. S1, S99–112. [Google Scholar] [CrossRef]
- Unamuno, X.; Gómez-Ambrosi, J.; Rodríguez, A.; Becerril, S.; Frühbeck, G.; Catalán, V. Adipokine dysregulation and adipose tissue inflammation in human obesity. Eur J Clin Invest. 2018, 48, e12997. [Google Scholar] [CrossRef] [PubMed]
- Ng, M.; Fleming, T.; Robinson, M.; Thomson, B.; Graetz, N.; Margono, C.; et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014, 384, 766–781. [Google Scholar] [CrossRef] [PubMed]
- Giles, D.A.; Moreno-Fernandez, M.E.; Divanovic, S. IL-17 Axis Driven Inflammation in Non-Alcoholic Fatty Liver Disease Progression. Curr Drug Targets. 2015, 16, 1315–1323. [Google Scholar] [CrossRef]
- Cozma, A.; Sitar-Taut, A.; Urian, L.; Fodor, A.; Suharoschi, R. Unhealthy lifestyle and the risk of metabolic syndrome- the Romanian experience. J Mind Med Sci. 2018, 5, 218–229. [Google Scholar] [CrossRef]
- Söderberg, C. 1.; Marmur, J.; Eckes, K.; Glaumann, H.; Sällberg, M.; Frelin, L.; Rosenberg, P.; Stål, P.; Hultcrantz, R. Microvesicular fat, inter cellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis. APMIS. 2011, 119, 412–420. [Google Scholar] [CrossRef] [PubMed]
- Strissel, K.J.; Stancheva, Z.; Miyoshi, H.; Perfield, J.W.; DeFuria, J.; Jick, Z.; et al. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes. 2007, 56, 2910–2918. [Google Scholar] [CrossRef]
- Ley, R.E.; Turnbaugh, P.J.; Klein, S.; Gordon, J.I. Microbial ecology: Human gut microbes associated with obesity. Nature. 2006, 444, 1022–1023. [Google Scholar] [CrossRef] [PubMed]
- Brun, P.; Castagliuolo, I.; Di Leo, V.; Buda, A.; Pinzani, M.; Palù, G.; et al. Increased intestinal permeability in obese mice: New evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2007, 292, G518–G525. [Google Scholar] [CrossRef]
- Abu-Shanab, A.; Quigley, E.M.M. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010, 7, 691–701. [Google Scholar] [CrossRef]
- Le Roy, T.; Llopis, M.; Lepage, P.; Bruneau, A.; Rabot, S.; Bevilacqua, C.; et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013, 62, 1787–1794. [Google Scholar] [CrossRef]
- Seremet, O.C.; Olaru, O.T.; Ilie, M.; Gutu, C.M.; Nitulescu, M.G.; Diaconu, C.; Motofei, C.; Margine, D.; Negres, S.; Zbarcea, C.E.; Stefanescu, E. Determination of pyrrolizidine alkaloids in dietary sources using a spectrophotometric method. J Mind Med Sci. 2018, 5, 294–299. [Google Scholar] [CrossRef]
- Rivera, C.A.; Adegboyega, P.; Rooijen, N. van Tagalicud, A.; Allman, M.; Wallace, M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 2007, 47, 571–579. [Google Scholar] [PubMed]
- Kubes, P.; Mehal, W.Z. Sterile Inflammation in the Liver. Gastroenterology. 2012, 143, 1158–1172. [Google Scholar]
- Miele, L.; Valenza, V.; La Torre, G.; Montalto, M.; Cammarota, G.; Ricci, R.; et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009, 49, 1877–1887. [Google Scholar] [CrossRef]
- Spruss, A.; Kanuri, G.; Wagnerberger, S.; Haub, S.; Bischoff, S.C.; Bergheim, I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology. 2009, 50, 1094–1104. [Google Scholar] [CrossRef]
- Bilzer, M.; Roggel, F.; Gerbes, A.L. Role of Kupffer cells in host defense and liver disease. Liver Int. 2006, 26, 1175–86. [Google Scholar] [CrossRef]
- Godfrey, D.I.; Hammond, K.J.; Poulton, L.D.; Smyth, M.J.; Baxter, A.G. NKT cells: Facts, functions and fallacies. Immunol Today. 2000, 21, 573–583. [Google Scholar] [PubMed]
- Nijhuis, J.; Rensen, S.S.; Slaats, Y.; van Dielen, F.M.H.; Buurman, W.A.; Greve, J.W.M. Neutrophil Activation in Morbid Obesity, Chronic Activation of Acute Inflammation. Obesity. 2009, 17, 2014–2018. [Google Scholar] [CrossRef]
- Alkhouri, N.; Morris-Stiff, G.; Campbell, C.; Lopez, R.; Tamimi, T.A.-R.; Yerian, L.; et al. Neutrophil to lymphocyte ratio: A new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2012, 32, 297–302. [Google Scholar] [CrossRef]
- Henning, J.R.; Graffeo, C.S.; Rehman, A.; Fallon, N.C.; Zambirinis, C.P.; Ochi, A.; et al. Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice. Hepatology. 2013, 58, 589–602. [Google Scholar] [CrossRef]
- Hammerich, L.; Heymann, F.; Tacke, F. Role of IL-17 and Th17 Cells in Liver Diseases. Clin Dev Immunol 2011, 2011, 345803. [Google Scholar] [CrossRef] [PubMed]
- Tang, Y.; Bian, Z.; Zhao, L.; Liu, Y.; Liang, S.; Wang, Q.; et al. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin Exp Immunol. 2011, 166, 281–290. [Google Scholar] [CrossRef] [PubMed]
- Davidson, A.; Diamond, B. Autoimmune Diseases. Mackay IR, Rosen FS, editors. N Engl J Med. 2001, 345, 340–350. [Google Scholar] [CrossRef] [PubMed]
- O’Shea, J.J.; Ma, A.; Lipsky, P. Cytokines and autoimmunity. Nat Rev Immunol. 2002, 2, 37–45. [Google Scholar] [CrossRef]
- Chalasani, N.; Younossi, Z.; Lavine, J.E.; Diehl, A.M.; Brunt, E.M.; Cusi, K.; et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012, 55, 2005–2023. [Google Scholar] [CrossRef]
- Gaffen, S.L. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009, 9, 556–567. [Google Scholar] [CrossRef]
- Lemmers, A.; Moreno, C.; Gustot, T.; Maréchal, R.; Degré, D.; Demetter, P.; et al. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology. 2009, 49, 646–657. [Google Scholar] [CrossRef]
- Bălănescu, P.; Lădaru, A.; Voiosu, T.; Nicolau, A.; Ene, M.; Bălănescu, E. Th17 and IL-17 immunity in chronic hepatitis C infection. Rom J Intern Med 2012, 50, 13–18. [Google Scholar]
- Qian, C.; Jiang, T.; Zhang, W.; Ren, C.; Wang, Q.; Qin, Q.; et al. Increased IL-23 and IL-17 expression by peripheral blood cells of patients with primary biliary cirrhosis. Cytokine. 2013, 64, 172–180. [Google Scholar] [CrossRef]
- Zhang, J.-P.; Yan, J.; Xu, J.; Pang, X.-H.; Chen, M.-S.; Li, L.; et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 2009, 50, 980–989. [Google Scholar] [CrossRef]
- Ahmed, M.; Gaffen, S.L. IL-17 in obesity and adipogenesis. Cytokine Growth Factor Rev. 2010, 21, 449–453. [Google Scholar] [CrossRef] [PubMed]
© 2019 by the author. 2019 Sorina Cezara Coste, Ionela Popovici, Andreea Maria Stefan, Iulia Breaban, Adela Sitar Taut, Simina Tarmure Sarlea, Angela Cozma, Dorel Sampelean, Olga Hilda Orasan, Vasile Negrean and Lucia Maria Procopciuc
Share and Cite
Coste, S.C.; Popovici, I.; Stefan, A.M.; Breaban, I.; Taut, A.S.; Sarlea, S.T.; Cozma, A.; Sampelean, D.; Orasan, O.H.; Negrean, V.; et al. Immune and Inflammatory Pathways in Non-Alcoholic Steatohepatitis (NASH). An Update. J. Mind Med. Sci. 2019, 6, 52-57. https://doi.org/10.22543/7674.61.P5257
Coste SC, Popovici I, Stefan AM, Breaban I, Taut AS, Sarlea ST, Cozma A, Sampelean D, Orasan OH, Negrean V, et al. Immune and Inflammatory Pathways in Non-Alcoholic Steatohepatitis (NASH). An Update. Journal of Mind and Medical Sciences. 2019; 6(1):52-57. https://doi.org/10.22543/7674.61.P5257
Chicago/Turabian StyleCoste, Sorina Cezara, Ionela Popovici, Andreea Maria Stefan, Iulia Breaban, Adela Sitar Taut, Simina Tarmure Sarlea, Angela Cozma, Dorel Sampelean, Olga Hilda Orasan, Vasile Negrean, and et al. 2019. "Immune and Inflammatory Pathways in Non-Alcoholic Steatohepatitis (NASH). An Update" Journal of Mind and Medical Sciences 6, no. 1: 52-57. https://doi.org/10.22543/7674.61.P5257
APA StyleCoste, S. C., Popovici, I., Stefan, A. M., Breaban, I., Taut, A. S., Sarlea, S. T., Cozma, A., Sampelean, D., Orasan, O. H., Negrean, V., & Procopciuc, L. M. (2019). Immune and Inflammatory Pathways in Non-Alcoholic Steatohepatitis (NASH). An Update. Journal of Mind and Medical Sciences, 6(1), 52-57. https://doi.org/10.22543/7674.61.P5257